Ustekinumab Biosimilar, Anti-human IL-12/IL-23 Antibody | Catalog C038P

Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody. The research grade ustekinumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Product Specifications

Catalog No.	C038P
Product Name	Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin 12, IL-12, IL12, IL23, IL-23, p40, IL12B, IL-12p40, Interleukin 23
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	Produced in mammalian cells.
Specificity	Specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays.
Formulation	0.2 µM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody evaluated for the treatment of T-cell driven autoimmune diseases. It targets and neutralizes interleukin-12 (IL-12) and interleukin-23 (IL-23), which are two proteins associated with inflammatory pathways.

Ustekinumab represents a therapeutic strategy for treating psoriasis, Multiple Sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.